Aridis Pharmaceuticals Inc (NASDAQ:ARDS) – Equities research analysts at Cantor Fitzgerald issued their FY2018 EPS estimates for Aridis Pharmaceuticals in a report released on Tuesday, September 11th, according to Zacks Investment Research. Cantor Fitzgerald analyst L. Chen expects that the company will post earnings of ($1.91) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Aridis Pharmaceuticals’ FY2019 earnings at ($3.02) EPS.
A number of other research firms have also recently weighed in on ARDS. Northcoast Research began coverage on shares of Aridis Pharmaceuticals in a research report on Monday, September 10th. They set an “outperform” rating and a $40.00 price objective on the stock. Northland Securities assumed coverage on shares of Aridis Pharmaceuticals in a research report on Monday, September 10th. They set an “outperform” rating on the stock. Finally, Laidlaw assumed coverage on shares of Aridis Pharmaceuticals in a report on Monday, September 10th. They issued a “buy” rating and a $23.00 price target on the stock.
ARDS stock traded up $0.12 during mid-day trading on Thursday, reaching $13.05. 3,300 shares of the stock traded hands, compared to its average volume of 22,650. Aridis Pharmaceuticals has a one year low of $11.25 and a one year high of $13.85.
Aridis Pharmaceuticals Company Profile
Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.
Featured Article: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.